Literature DB >> 30559217

ADAR2-mediated Q/R editing of GluK2 regulates kainate receptor upscaling in response to suppression of synaptic activity.

Sonam Gurung1, Ashley J Evans1, Kevin A Wilkinson1, Jeremy M Henley2.   

Abstract

Kainate receptors (KARs) regulate neuronal excitability and network function. Most KARs contain the subunit GluK2 (also known as GRIK2), and the properties of these receptors are determined in part by ADAR2 (also known as ADARB1)-mediated mRNA editing of GluK2, which changes a genomically encoded glutamine residue into an arginine residue (Q/R editing). Suppression of synaptic activity reduces ADAR2-dependent Q/R editing of GluK2 with a consequential increase in GluK2-containing KAR surface expression. However, the mechanism underlying this reduction in GluK2 editing has not been addressed. Here, we show that induction of KAR upscaling, a phenomenon in which surface expression of receptors is increased in response to a chronic decrease in synaptic activity, results in proteasomal degradation of ADAR2, which reduces GluK2 Q/R editing. Because KARs incorporating unedited GluK2(Q) assemble and exit the ER more efficiently, this leads to an upscaling of KAR surface expression. Consistent with this, we demonstrate that partial ADAR2 knockdown phenocopies and occludes KAR upscaling. Moreover, we show that although the AMPA receptor (AMPAR) subunit GluA2 (also known as GRIA2) also undergoes ADAR2-dependent Q/R editing, this process does not mediate AMPAR upscaling. These data demonstrate that activity-dependent regulation of ADAR2 proteostasis and GluK2 Q/R editing are key determinants of KAR, but not AMPAR, trafficking and upscaling.This article has an associated First Person interview with the first author of the paper.
© 2018. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  ADAR2; AMPA receptor; GluA2; GluK2; Homeostatic plasticity; Kainate receptor; Scaling; Synapse; mRNA editing

Mesh:

Substances:

Year:  2018        PMID: 30559217      PMCID: PMC6307878          DOI: 10.1242/jcs.222273

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  39 in total

1.  Identification of critical functional determinants of kainate receptor modulation by auxiliary protein Neto2.

Authors:  Theanne N Griffith; Geoffrey T Swanson
Journal:  J Physiol       Date:  2015-09-20       Impact factor: 5.182

2.  RNA editing in brain controls a determinant of ion flow in glutamate-gated channels.

Authors:  B Sommer; M Köhler; R Sprengel; P H Seeburg
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

3.  Metabotropic action of postsynaptic kainate receptors triggers hippocampal long-term potentiation.

Authors:  Milos M Petrovic; Silvia Viana da Silva; James P Clement; Ladislav Vyklicky; Christophe Mulle; Inmaculada M González-González; Jeremy M Henley
Journal:  Nat Neurosci       Date:  2017-02-13       Impact factor: 24.884

4.  ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia.

Authors:  Peter L Peng; Xiafen Zhong; Weihong Tu; Mangala M Soundarapandian; Peter Molner; Dongya Zhu; Lorraine Lau; Shuhong Liu; Fang Liu; Youming Lu
Journal:  Neuron       Date:  2006-03-02       Impact factor: 17.173

5.  Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence.

Authors:  J Egebjerg; V Kukekov; S F Heinemann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

6.  Structure and assembly mechanism for heteromeric kainate receptors.

Authors:  Janesh Kumar; Peter Schuck; Mark L Mayer
Journal:  Neuron       Date:  2011-07-28       Impact factor: 17.173

Review 7.  Kainate receptors coming of age: milestones of two decades of research.

Authors:  Anis Contractor; Christophe Mulle; Geoffrey T Swanson
Journal:  Trends Neurosci       Date:  2011-01-20       Impact factor: 13.837

Review 8.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Authors:  D Chen; M Frezza; S Schmitt; J Kanwar; Q P Dou
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

9.  AMPA receptor tetramerization is mediated by Q/R editing.

Authors:  Ingo H Greger; Latika Khatri; Xiangpeng Kong; Edward B Ziff
Journal:  Neuron       Date:  2003-11-13       Impact factor: 17.173

10.  Clathrin-independent trafficking of AMPA receptors.

Authors:  Oleg O Glebov; Cezar M Tigaret; Jack R Mellor; Jeremy M Henley
Journal:  J Neurosci       Date:  2015-03-25       Impact factor: 6.167

View more
  5 in total

Review 1.  Structure, Function, and Regulation of the Kainate Receptor.

Authors:  Surbhi Dhingra; Juhi Yadav; Janesh Kumar
Journal:  Subcell Biochem       Date:  2022

2.  Membrane and synaptic defects leading to neurodegeneration in Adar mutant Drosophila are rescued by increased autophagy.

Authors:  Anzer Khan; Simona Paro; Leeanne McGurk; Nagraj Sambrani; Marion C Hogg; James Brindle; Giuseppa Pennetta; Liam P Keegan; Mary A O'Connell
Journal:  BMC Biol       Date:  2020-02-14       Impact factor: 7.431

3.  Reduction of A-to-I RNA editing in the failing human heart regulates formation of circular RNAs.

Authors:  Karoline E Kokot; Jasmin M Kneuer; David John; Sabine Rebs; Maximilian N Möbius-Winkler; Stephan Erbe; Marion Müller; Michael Andritschke; Susanne Gaul; Bilal N Sheikh; Jan Haas; Holger Thiele; Oliver J Müller; Susanne Hille; Florian Leuschner; Stefanie Dimmeler; Katrin Streckfuss-Bömeke; Benjamin Meder; Ulrich Laufs; Jes-Niels Boeckel
Journal:  Basic Res Cardiol       Date:  2022-06-23       Impact factor: 12.416

4.  Neurotrophic effects of Botulinum neurotoxin type A in hippocampal neurons involve activation of Rac1 by the non-catalytic heavy chain (HCC/A).

Authors:  Luis Solabre Valois; Vanilla Hua Shi; Paul Bishop; Bangfu Zhu; Yasuko Nakamura; Kevin A Wilkinson; Jeremy M Henley
Journal:  IBRO Neurosci Rep       Date:  2021-05-13

5.  Spatiotemporal Regulation of Transcript Isoform Expression in the Hippocampus.

Authors:  Joun Park; Shannon Farris
Journal:  Front Mol Neurosci       Date:  2021-07-08       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.